FOLH1 and prostate carcinoma: Interestingly, heterodimeric 177Lu-radiopharmaceuticals simultaneously targeting PSMA and Bombesin (Lu-DOTA-iPSMA-Lys-BN) have been synthesized and shown to be taken up by human PC3 and LNCaP prostate cancer cells [167].